Women Over 40

The transition, named early: perimenopause — the years of winding-down ovarian function — often begins in the late 30s and 40s, with irregular cycles, vasomotor symptoms, and sleep disruption arriving well before anyone applies the word; menopause itself is the twelve-month mark (average age ~51). Estrogen's decline drives the cascade: temperature regulation, sleep architecture, bone turnover, lipid patterns, and the genitourinary changes almost nobody discusses. The foundational reframe: a normal transition, not a disease — and symptoms that are genuinely treatable.

The bone window: the five to ten years around the transition carry the fastest bone loss of a woman's life — roughly one to two percent yearly (the Bone page's menopause window, told from this side). The defense team assembles before and through it: vitamin D opening the calcium gate, dietary calcium, protein building the collagen frame, and loading signaling where it lands — strength training as the mechanical half of the defense. DEXA screening begins routinely at 65, earlier with risks — the conversation worth requesting at the transition.

The heart clock and HRT, honestly: women's cardiovascular risk runs about a decade behind men's — then accelerates after the transition, with lipid patterns shifting as estrogen's protection exits (the Men's page's timing-gap, told from this side). And hormone therapy — the most under-served conversation in women's health — deserves its full nuance: the 2002 Women's Health Initiative frightened a generation off HRT; the recalibrated evidence (the timing hypothesis) finds symptomatic women under 60 or within ten years of menopause often see net benefit, especially for vasomotor relief and bone. It is an individualized clinical decision — real benefits, real trade-offs, and neither the shelf's answer nor the silence's.

The symptoms and the calendar: vasomotor symptoms are treatable — hormonal therapy most effective, genuine non-hormonal options existing now; sleep disruption (the night cost) answering to the Sleep pages' pillars plus symptom treatment; brain fog — real during the transition, and the honest research finding: usually resolving post-transition; mood — the calibrated nuance: the transition stresses rather than inherently causes, and support is real. The screening calendar: mammography from 40–45 (the guideline conversation), cervical screening to 65, colonoscopy at 45, thyroid checked (women's rates run higher), and iron's flip — needs fall with menstruation's end, while any postmenopausal bleeding is always a flag. The pillars close it: strength, protein, sleep, and the partnership — held through and after the window.

• Perimenopause begins years before it's named — the late 30s and 40s count.
• The transition is normal; the symptoms are treatable; the silence is optional.
• The bone window: ~1–2% yearly for 5–10 years — the defense team, assembled early.
• Heart risk: a decade behind, then accelerating — lipids shift at the transition.
• HRT: the timing hypothesis — individualized, clinical, neither taboo nor default.
• Brain fog through the transition is real — and usually resolves after.
• Postmenopausal bleeding is always a prompt evaluation — no exceptions.